Sign In
Buy IMUX
$14.17
-0.470 (-3.21%)
At Close: Jun 03, 2026
As SpaceX reportedly snips IPO valuation, prediction markets are still saying it will be a $2 trillion company
07:01am, Friday, 29'th May 2026
Prediction market traders are pricing a 78% chance that SpaceX closes its first day of trading above $2 trillion, a valuation that would rank it among the...
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
10:30am, Thursday, 28'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-break
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Hi
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
06:29am, Thursday, 28'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in...
FTSE 100 Live: Global markets hit record highs, oil prices slide as Iran deal awaited
01:12pm, Wednesday, 27'th May 2026
FTSE 100 up 13 points at 10,505 Asian and US tech stocks drive new global markets to all-time highs Energy prices and govt bonds ease on Iran optimism UK...
Amazon shares have room to run as AWS AI backlog hits $35B, UBS says
11:42am, Wednesday, 27'th May 2026
Amazon.com Inc (NASDAQ:AMZN) is significantly underappreciated by Wall Street as artificial intelligence commitments pile up in its cloud division, UBS...
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
09:08am, Wednesday, 27'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-s
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
06:30am, Wednesday, 27'th May 2026
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transi
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
06:25am, Wednesday, 27'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its CEO as the company advances its multiple sclerosis treatment...
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
06:17am, Wednesday, 27'th May 2026
Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic'
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
09:35am, Tuesday, 19'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of it
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
06:30am, Tuesday, 19'th May 2026
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK,
Immunic advances Phase 3 MS program, eyes topline data by year-end
09:18am, Wednesday, 13'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
06:30am, Wednesday, 13'th May 2026
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.
Immunic advances Phase 3 MS program, eyes topline data by year-end
05:04am, Wednesday, 13'th May 2026
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate,...
